Information Provided By: 
Fly News Breaks for June 1, 2015
CLVS
Jun 1, 2015 | 07:37 EDT
JPMorgan recommends using the today's weakness in shares of Clovis as a buying opportunity. The firm calls Clovis's rociletinib update at ASCO "not-so-straight forward," but believes the company remains well positioned with "two promising, wholly owned, late stage oncology compounds." It reiterates an Overweight rating on the name.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
